Noriyuki Ebi

1.1k total citations
52 papers, 639 citations indexed

About

Noriyuki Ebi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Noriyuki Ebi has authored 52 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Noriyuki Ebi's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Noriyuki Ebi is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Noriyuki Ebi collaborates with scholars based in Japan and United States. Noriyuki Ebi's co-authors include Isamu Okamoto, Toshiyuki Sawa, Nobuyuki Katakami, Takashi Nishimura, Tatsuhiko Kashii, T. Hirashima, Y. Ichinose, Satoshi Kudoh, M. Fukuoka and Kazuhiko Shibata and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Noriyuki Ebi

46 papers receiving 626 citations

Peers

Countries citing papers authored by Noriyuki Ebi

Since Specialization

Citations

This map shows the geographic impact of Noriyuki Ebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noriyuki Ebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noriyuki Ebi more than expected).

Fields of papers citing papers by Noriyuki Ebi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noriyuki Ebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noriyuki Ebi. The network helps show where Noriyuki Ebi may publish in the future.

Co-authorship network of co-authors of Noriyuki Ebi

This figure shows the co-authorship network connecting the top 25 collaborators of Noriyuki Ebi. A scholar is included among the top collaborators of Noriyuki Ebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noriyuki Ebi. Noriyuki Ebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model 2025 ·Scientific Reports ·Hiroyuki Inoue, Takayuki Hamasaki, Kazuhiko Inoue, Akira Nakao, Noriyuki Ebi, (unknown), Ichiro Nagata, M. Fujita, (unknown)	1
2	Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 2024 ·JTO Clinical and Research Reports ·Takehiro Tozuka, Yuji Minegishi, Ou Yamaguchi, Kana Watanabe, Yukihiro Toi, Ryota Saito, Yoshiaki Nagai, Yosuke Tamura, (unknown), (unknown), Noriyuki Ebi, Kosuke Sakai, Nobuhiro Kanaji, Makoto Izumi, (unknown), Satoshi Watanabe, Satoshi Morita, Kunihiko Kobayashi, Masahiro Seike	2
3	Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy 2024 ·Anticancer Research ·Noriyuki Ebi, Hiroyuki Inoue, (unknown), (unknown), Eriko Kinoshita, (unknown), (unknown), Yusuke Osaki, (unknown), Akira Nakao, (unknown), Naoki Hamada, Masaki Fujita	4
4	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L) 2021 ·Journal of Thoracic Oncology ·Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda, Hirotsugu Kenmotsu, Hiroshi Mukae, Kentaro Ito, (unknown), (unknown), Satoru Miura, Kentaro Tanaka, Noriyuki Ebi, Takayuki Suetsugu, Taishi Harada, Keisuke Kirita, Toshihide Yokoyama, Yuki Nakatani, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio	41
5	A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) 2020 ·BMC Cancer ·Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, (unknown), Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio	8
6	Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408 2019 ·Journal of Clinical Medicine ·Koichi Takayama, Junji Uchino, Masaki Fujita, Shoji Tokunaga, (unknown), Ryotaro Morinaga, Noriyuki Ebi, Sho Saeki, (unknown), Hiroshi Wataya, Tadaaki Yamada, Yoichi Nakanishi	1
7	Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201) 2019 ·Lung Cancer ·Minoru Fukuda, Takeshi Kitazaki, (unknown), Masao Ichiki, Hiroshi Mukae, Riichiroh Maruyama, (unknown), Midori Shimada, Takaya Ikeda, Junji Kishimoto, Taishi Harada, Takashi Seto, Noriyuki Ebi, Koichi Takayama, Isamu Okamoto, Yukito Ichinose, Kenji Sugio	11
8	A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol 2018 ·Clinical Lung Cancer ·Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose	8
9	OA08.02 Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101) 2017 ·Journal of Thoracic Oncology ·Keiichi Ota, Yoshimasa Shiraishi, Taishi Harada, Daisuke Himeji, Takeshi Kitazaki, Noriyuki Ebi, Akinobu Hamada, Takeharu Yamanaka, Kaname Nosaki, Mitsuhiro Takenoyama, Kenji Sugio	10
10	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study 2017 ·Cancer Chemotherapy and Pharmacology ·Yuki Kataoka, Katsuya Hirano, (unknown), Satoshi Hara, Daichi Fujimoto, (unknown), Noriyuki Ebi, Keisuke Tomii, Hiroshige Yoshioka	6
11	The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study 2016 ·Journal of Infection and Chemotherapy ·Masaki Fujita, Takemasa Matsumoto, (unknown), Hiroshi Wataya, Koichi Takayama, Masayuki Ishida, Noriyuki Ebi, Junji Kishimoto, Yukito Ichinose	3
12	A Community-acquired Lung Abscess Attributable to <i>Streptococcus pneumoniae</i> which Extended Directly into the Chest Wall 2016 ·Internal Medicine ·(unknown), Kazunori Tobino, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yoshikazu Yamaji, (unknown), Hiroyuki Miyajima, (unknown), Noriyuki Ebi	4
13	Localized Pleural Metastases of Renal Cell Carcinoma After Nephrectomy 2015 ·Journal of Bronchology & Interventional Pulmonology ·(unknown), Kazunori Tobino, (unknown), (unknown), Yoshikazu Yamaji, (unknown), (unknown), Noriyuki Ebi	4
14	The utility and safety evaluation of ultrasonography guided transthoracic biopsy 2014 ·European Respiratory Journal ·Yoshikazu Yamaji, Kazunori Tobino, (unknown), (unknown), Keisuke Anan, (unknown), (unknown), Noriyuki Ebi	1
15	Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301 2010 ·Journal of Thoracic Oncology ·Masashi Kobayashi, Kaoru Matsui, Yasuo Iwamoto, Noriyuki Ebi, Satoshi Oizumi, Koji Takeda, Toshiyuki Sawa, Kazuhiko Shibata, Hideo Saka, Fumio Imamura, Nobuhiko Seki, Hiroshi Saito, Isao Goto, Kazuhiko Nakagawa	11
16	Huge Mediastinal Cystic Tumor Penetrating the Sternum 2010 ·The Annals of Thoracic Surgery ·(unknown), Toshihiro Osaki, Mantaro Kodate, Noriyuki Ebi, Masafumi Oya, Hidehiko Yamamoto	2
17	A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Noriyuki Ebi, Hiroshi Semba, (unknown), Koichi Takayama, Hiroshi Wataya, Takashige Kuraki, Hidehiko Yamamoto, (unknown), Isamu Okamoto, Yoichi Nakanishi	37
18	P3-151: EGFR mutation–based phase II multicenter trial of gefitinib in patients with advanced non–small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0403) 2007 ·Journal of Thoracic Oncology ·Yoshiko Urata, Takashi Seto, Isamu Okamoto, Tatsuhiko Kashii, Tomonori Hirashima, S. Kudoh, Noriyuki Ebi, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka	2
19	Second-line chemotherapy for relapsed small cell lung cancer 1997 ·Japanese Journal of Clinical Oncology ·Noriyuki Ebi	40
20	Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. 1997 ·Journal of Clinical Oncology ·Kaoru Kubota, Yutaka Nishiwaki, Ryutaro Kakinuma, Fumihiko Hojo, T Matsumoto, Hironobu Ohmatsu, Ikuo Sekine, Michiya Yokozaki, Kōichi Goto, Noriyuki Ebi, Tetsuro Kodama	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact